TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00233259

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Usual Diabetes Care Control group
Study: NCT02430662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
Study: NCT02825108

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra uterine injection of tissue culture medium +ET
Description: ) only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ET
Description: the embryo transfer ( ET) is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
Study: NCT02006927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve Stimulation
Description: Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
Study: NCT02621892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02920320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based self-help program
Study: NCT01358162

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given orally, daily for 14 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
Study: NCT01217034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE with sorafenib
Description: Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE alone
Description: TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.
Study: NCT05239078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Inferior alveolar nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: Inferior alveolar nerve block
Study: NCT02430662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT02059213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupron Depot

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron Depot
Study: NCT02242825

Intervention type: DRUG
Intervention: Micardis®

Intervention type: DRUG
Intervention: MicardisPlus®
Study: NCT05239078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: Inferior alveolar nerve block
Study: NCT00673920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate.
Study: NCT00358917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 800/200 mg once-daily (QD) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 400/100 mg twice-daily (BID) tablet
Study: NCT00062114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study: NCT00568958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS counseling
Description: Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BASICS counseling
Description: Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
Study: NCT00673920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous repeating dose
Study: NCT01071161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Description: azithromycin, tablets, during 12 weeks, three times a week, 250mg
Study: NCT00568958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
Study: NCT01071161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00285051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled delta-8-THC 300mcg or 600mcg per dose
Description: drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled delta-8-THC 300mcg or 600mcg per dose
Description: drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled delta-8-THC 300mcg or 600mcg per dose
Description: drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled delta-8-THC 300mcg or 600mcg per dose
Description: drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC
Study: NCT03641196

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed appliance
Description: Use of a cemented modified palatal Nance appliance presenting a bite-plane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Composite bite plane
Description: treatment with a composite build up in the palatal aspect of the upper central incisors.
Study: NCT00085527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depsipeptide
Study: NCT01924780

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation 10 minutes
Description: NEMOS transvagal stimuli 10 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation 10 minutes
Description: NEMOS transvagal stimuli 10 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stimulation 10 minutes
Description: NEMOS transvagal stimuli 10 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEMOS transvagal stimulation 60 minutes
Description: NEMOS Device stimulation in 60 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEMOS transvagal stimulation 60 minutes
Description: NEMOS Device stimulation in 60 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NEMOS transvagal stimulation 60 minutes
Description: NEMOS Device stimulation in 60 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEMOS Device sham stimulation 10 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEMOS Device sham stimulation 10 minutes
Study: NCT02509767

Intervention type: DRUG
Group type: OTHER
Intervention: Subcutaneous depot medroxyprogesterone acetate
Description: Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous depot medroxyprogesterone acetate
Description: Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
Study: NCT03986424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akatinol Memantine 20 mg
Description: Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Akatinol Memantine 10 mg
Description: Akatinol Memantine 10 mg to be taken orally, twice daily
Study: NCT00670020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supplemental perioperative oxygen
Description: increased perioperative oxygen verses non-interventional oxygen
Study: NCT01533519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y
Description: Intranasal administration will be administered with a nasal drug delivery device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y
Description: Intranasal administration will be administered with a nasal drug delivery device.
Study: NCT01918163

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate pills
Study: NCT01943799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: Administered as a subcutaneous injection every 4 weeks for a total of 6 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: Administered as a subcutaneous injection every 4 weeks for a total of 6 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4774
Description: Administered as a subcutaneous injection every 4 weeks for a total of 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OAV Regimen
Description: Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OAV Regimen
Description: Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OAV Regimen
Description: Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OAV Regimen
Description: Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
Study: NCT00687388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: selective alpha 1-blockers
Description: Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: 200mg daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-blocker and NSAID
Description: amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
Study: NCT02884544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100
Description: Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100
Description: Treatment
Study: NCT00568958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo naltrexone
Description: Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
Study: NCT04037436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength and Balance Training & Nutrition Education
Description: Exercise:A kinesiologist-led twice-weekly program. Prior to attending the program, each attendee gets a 1:1 session with the kinesiologist to decide exercise starting levels. Group exercises start with a warm-up stepping game. Participants then perform 2 sets of 8 repetitions of each exercise, gradually progressing to an intensity of 3-8 repetitions maximum. Exercises include one each of a push, pull, squat, reach/press, lunge/step-up, lift and carry movement. After, there is a 10-minute group discussion to prompt making exercise routine at home. Nutrition:Two dietitian-led interactive group seminars to promote strategies to increase protein intake and sampling of protein-rich snacks and protein supplements. Seminar topics consider the cost to prepare high protein foods, the ability of retirement home residents to alter diet, how and why to spread protein intake through the day, how much protein is in their usual choices, and easy-to-consume protein-rich snacks.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: During periods when a site is not involved in the MoveSTroNg program, participants will continue with their usual care routine. Usual care routines should not involve strength and balance exercises.
Study: NCT01051986

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saphenous vein composite grafting
Description: use saphenous vein as a composite graft connected to the left internal thoracic artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right internal thoracic artery composite grafting
Description: right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
Study: NCT00556218

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tibetan Meditation Program
Description: 12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Meditation
Description: No meditation; usual care.
Study: NCT03179514

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc.

Intervention type: DRUG
Group type: OTHER
Intervention: Lipid Regulating Drugs
Description: Mainly including statins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Regulating Drugs
Description: Mainly including statins

Intervention type: DRUG
Group type: OTHER
Intervention: Coronary Vasodilator
Description: Mainly including nitrates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coronary Vasodilator
Description: Mainly including nitrates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gualou Xiebai Banxia Decoction & Danshen Decoction
Description: Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
Study: NCT01717664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-104
Description: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
Study: NCT01151046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane (25 mg) administered orally once per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: Exemestane (25 mg) administered orally once per day
Study: NCT00849121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP with rhGM-CSF
Description: pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP with rhGM-CSF
Description: pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
Study: NCT00127530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine-SR
Description: Tablets, 10 mg, twice daily, 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill, twice a day (b.i.d.)